British Journal of Cancer

TABLE 2

FROM:

Risks and benefits of bisphosphonates

R E Coleman

BACK TO ARTICLE

Table 2. Clinical trials of bisphosphonates to prevent metastasis

Figure and tables index
Agent and trial descriptor Setting Treatment and duration Study size and status
Clodronate (oral)
 NSABP-B34Stage I–III breast cancer3 years clodronate vs placebo3400Accrual complete
     
Zoledronic acid (iv)
 AZUREStage II/III breast cancer5 years zoledronic acid vs control3360Accrual complete
 Z-FAST/ZO-FAST/EZO-FASTStage I–III breast cancerImmediate vs delayed zoledronic acid2193Accrual complete
 ABCSG XIIStage I-II breast cancer6 monthly zoledronic acid vs control1800Accrual complete
 SUCCESSStage I–III breast cancer3 vs 5 years zoledronic acid3754Acccrual ongoing
 ZEUSHigh-risk prostate cancer3 years zoledronic acid vs control1433Accrual complete
 2419Stage IIIA/IIIB NSCLC2 years zoledronic acid vs control446Accrual ongoing
     
Ibandronate (oral)
 GAINStage II/III breast cancer2 years ibandronate vs control>3000Accrual ongoing
     
Others
 S0307/IntergroupStage I–III breast cancer3 years clodronate vs zoledronic acid vs ibandronate4500Accrual ongoing
Figure and tables index
BACK TO ARTICLE